Home › Carcinoma polmonare a piccole cellule › Florida › Orlando
Studi clinici su Carcinoma polmonare a piccole cellule a Orlando, FL
15 studi su Carcinoma polmonare a piccole cellule cercano partecipanti presso sedi a Orlando e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
In reclutamentoFase 1/2
- Advent Health, Orlando
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
In reclutamentoFase 1
- AdventHealth Cancer Institute, Orlando
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
In reclutamentoFase 3
- Orlando Health Cancer Institute /ID# 280418, Orlando
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
In reclutamentoFase 1
- Sara Cannon Research Institute Lake Nona, Orlando
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
In reclutamentoFase 3
- University of Florida Health Cancer Center at Orlando Health, Orlando
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
In reclutamentoFase 3
- Clermont Oncology Center, Clermont · a 24 mi di distanza
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
In reclutamentoFase 1/2
- Avenzo Therapeutics Recruiting Site, Orlando
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
In reclutamentoFase 2
- Clermont Oncology Center, Clermont · a 24 mi di distanza
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- AdventHealth Celebration, Celebration · a 17 mi di distanza
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
In reclutamentoFase 3
- AdventHealth Orlando, Cancer Institute, Orlando
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
In reclutamentoFase 1
- Florida Cancer Specialists, Orlando
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
In reclutamentoFase 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Study of LY4175408 in Participants With Advanced Cancer
In reclutamentoFase 1
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Florida Cancer Specialists-Lake Nona, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · a 17 mi di distanza
Studi su Carcinoma polmonare a piccole cellule in altre città
- Houston, TX26 studi
- Arlington, VA23 studi
- Boston, MA21 studi
- New York City, NY21 studi
- Nashville, TN20 studi
- Los Angeles, CA20 studi
- Dallas, TX13 studi
- St. Louis, MO13 studi
- Cleveland, OH13 studi
- Detroit, MI12 studi
- Chicago, IL12 studi
- Washington, DC12 studi
Altri studi a Orlando
- Cancro del polmone non a piccole cellule44 studi
- Obesità31 studi
- Cancro metastatico29 studi
- Sovrappeso27 studi
- Morbo di Alzheimer25 studi
- Diabete di tipo 224 studi
- Cancro (tutti i tipi)24 studi
- Cancro al seno23 studi
- Cancro ovarico22 studi
- Colite ulcerosa22 studi
- Cancro ai polmoni21 studi
- Cancro colorettale19 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.